Chimeric Therapeutics (ASX: CHM) newly appointed COO Jennifer Chow joined Steve Darling from Proactive to talk about her vision for the company. Chow talks about her background working in cell therapy and how Chimeric hopes to be a big player in it.
Chow also told Proactive about their lead drug CLTX-CAR T which is currently in Phase 1 clinical trials. That drug look to be a treatment for patients with Glioblastoma and potentially other cancers as well.